Of all somatic mutations identified in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), TP53 mutations are associated with the most inferior outcomes across independent studies, with a median OS of 6–12 months [1,2,3]. Here, TP53 is linked to myelodysplastic syndrome.